Screener
Zevra Therapeutics, Inc. ZVRA Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Zevra Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001434647-26-000068
FAQ
- What is Zevra Therapeutics, Inc.'s retained earnings?
- Zevra Therapeutics, Inc. (ZVRA) reported retained earnings of -$375.42M in Q2 2026.
- How has Zevra Therapeutics, Inc.'s retained earnings changed year-over-year?
- Zevra Therapeutics, Inc.'s retained earnings increased by 13.4% year-over-year, from -$433.68M to -$375.42M.
- What is the long-term trend for Zevra Therapeutics, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s retained earnings has grown at a 10.3% compound annual growth rate (CAGR), from -$258.47M to -$422.06M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Zevra Therapeutics, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude